Olanap 5

Indications

Olanap is prescribed for the acute and maintenance treatment of schizophrenia and related psychotic disorders characterized by prominent positive symptoms (such as delusions, hallucinations, disordered thinking, hostility, and suspiciousness) as well as negative symptoms (including flattened affect, emotional and social withdrawal, and poverty of speech). It is also indicated for managing acute manic or mixed episodes in bipolar disorder, with or without psychotic features and rapid cycling.

Consult a registered healthcare professional before using this medication.

Pharmacology

Olanap contains Olanzapine, an antipsychotic agent that interacts with several receptors, including serotonin (5HT2A/2C, 5HT3, 5HT6), dopamine (D1, D2, D3, D4, D5), cholinergic muscarinic (M1-M5), α1 adrenergic, and histamine (H1) receptors. While the exact mechanism of action for Olanzapine in treating schizophrenia is not fully understood, it is believed to involve a combination of dopamine and serotonin type 2 (5HT2) antagonism. Olanzapine is well absorbed orally, achieving peak plasma levels within 5 to 8 hours, and food does not affect its absorption. It is neither mutagenic nor carcinogenic.

Dosage

For schizophrenia and combination therapy in bipolar disorder, the initial dose is 5-10 mg once daily. The daily dosage may be adjusted based on the patient’s clinical status, typically within the range of 5-20 mg. Doses exceeding 10 mg should only be given after reassessment, with a maximum limit of 20 mg daily.

For monotherapy in mania, start with 15 mg once daily, adjusting as needed within the 5-20 mg range. Doses above 15 mg should be reassessed, with a maximum of 20 mg daily.

Consult a registered healthcare professional before using this medication.

Administration

Olanap can be taken without regard to meals. Gradual dose reduction should be considered when discontinuing Olanzapine.

Consult a registered healthcare professional before using this medication.

Interactions

Olanap may antagonize the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucuronyl transferase enzymes (e.g., Omeprazole, Rifampicin) can increase Olanap clearance. Inhibitors of CYP1A2 may slow Olanap elimination. Carbamazepine may also increase Olanap clearance, and the concurrent use of activated charcoal can reduce its oral bioavailability by 50-60%. Caution is advised when using Olanap with centrally acting drugs and alcohol.

Contraindications

Olanzapine is contraindicated in patients with a known hypersensitivity to any component of the product and in those at risk for narrow-angle glaucoma.

Side Effects

Common side effects include somnolence and weight gain, along with increased appetite, elevated glucose and triglyceride levels, dizziness, akathisia, Parkinsonism, dyskinesia, orthostatic hypotension, mild anticholinergic effects (such as constipation and dry mouth), asthenia, edema, and photosensitivity reactions.

Pregnancy & Lactation

Olanzapine should only be used during pregnancy if the potential benefits outweigh the risks to the fetus. Patients should inform their healthcare provider if they become pregnant or plan to during treatment. There are no reports of teratogenic effects, but breastfeeding is not recommended while taking Olanzapine.

Precautions & Warnings

Olanap should be used cautiously in patients with a history of seizures or conditions that may provoke seizures. It is also advised for those with low leukocyte or neutrophil counts, drug-induced bone marrow depression, impaired liver function, and those on hepatotoxic or centrally acting medications, especially in older adults. Patients should be warned against operating heavy machinery or driving.

Use in Special Populations

• Children: Not studied in individuals under 18 years.
• Elderly (65+ years): Start with a dose of 5 mg/day.
• Patients with hepatic or renal impairment: Start with a dose of 5 mg/day.

Therapeutic Class

Atypical neuroleptic drugs.

Storage Conditions

Store below 30°C, away from light and moisture. Keep out of reach of children.